At this point, for research purposes, it should not be used
Because it degrades in blood in a pathway involving amino-peptidases, it may not be suitable for people who take medications that inhibit or are metabolized by peptidases (e.g., captopril, a treatment for hypertension).4 Also, based on what we know about other therapeutic peptides, we would say DSIP is contraindicated for women who are pregnant or breastfeeding as well as people with a personal history of cancer
These findings suggest that CagriSema could represent a highly effective therapeutic option for both weight and glycaemic management in people with Type 2 diabetes
Study selection Two of the authors (IP, MP) performed the eligibility assessment in an independent, unblinded and standardised manner
However, the use of synthetic growth hormone comes with several drawbacks